1. Home
  2. GKOS vs ONON Comparison

GKOS vs ONON Comparison

Compare GKOS & ONON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$185.49

Market Cap

10.9B

Sector

Health Care

ML Signal

N/A

Logo On Holding AG

ONON

On Holding AG

N/A

Current Price

$32.22

Market Cap

12.4B

ML Signal

N/A

Company Overview

Basic Information
Metric
GKOS
ONON
Founded
1998
2010
Country
United States
Switzerland
Employees
1094
N/A
Industry
Medical/Dental Instruments
Shoe Manufacturing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
10.9B
12.4B
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
GKOS
ONON
Price
$185.49
$32.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
20
Target Price
$126.92
$60.15
AVG Volume (30 Days)
855.1K
6.8M
Earning Date
04-29-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$507,442,000.00
N/A
Revenue This Year
$23.32
$19.58
Revenue Next Year
$27.43
$19.98
P/E Ratio
N/A
$56.05
Revenue Growth
32.33
N/A
52 Week Low
$73.16
$30.11
52 Week High
$189.69
$51.08

Technical Indicators

Market Signals
Indicator
GKOS
ONON
Relative Strength Index (RSI) 74.68 37.17
Support Level $99.75 $31.52
Resistance Level N/A $38.63
Average True Range (ATR) 7.77 1.21
MACD 1.39 -0.67
Stochastic Oscillator 88.29 23.92

Price Performance

Historical Comparison
GKOS
ONON

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About ONON On Holding AG

Founded in Switzerland in 2010, sportswear firm On Holding generates more than 90% of its sales from athletic shoes. The brand is best known for its running shoes and its distinctive CloudTec soles. On also produces athletic apparel (6% of 2025 sales) and accessories (1%). The firm's merchandise is available in more than 80 countries and is sold through both wholesale (58% of sales) and company-owned channels (42%). In 2025, On generated 58% of its sales in North America, 25% in Europe, the Middle East, and Africa, and 17% in the Asia-Pacific region.

Share on Social Networks: